For research use only
| Cat No. | ABC-TC0232 |
| Product Type | Human Lymphocytes Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Burkitt’s Lymphoma |
| Product Code | EB-1; Epstein-Barr-1 |
The EB1 cell line was isolated by M.A. Epstein and Y.M. Barr in 1963 from biopsy fragments and cell clumps of a lymphoma.
EB1 is a human Burkitt lymphoma cell line isolated from biopsy fragments and cell clumps obtained from a 9-year-old African female patient with Burkitt lymphoma. The cell line exhibits lymphoblast morphology with large nuclei and microvilli formation and demonstrates suspension growth properties in culture. Cytogenetic analysis confirms that EB1 cells have an aneuploid chromosome composition, with characterized EB1 cellular processes and EB1 protein interactions underlying its malignant phenotype. The cells express EGFR. EB1 demonstrates strong tumorigenic potential and exhibits metastatic potential, with cells disseminating to regional lymph nodes in xenograft models. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | EB-1; Epstein-Barr-1 |
| Species | Human |
| Cat.No | ABC-TC0232 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Burkitt’s Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphocytes Cell Lines |
EB1 cells serve as a critical in vitro model for studying Burkitt lymphoma pathogenesis and therapeutic interventions. This well-characterized B-lymphoblast cell line enables drug sensitivity screening within oncology projects, assessing compound efficacy against lymphoma-specific targets. Its comprehensive genomic and transcriptomic profiling supports functional genetic studies, including investigations into TP53 mutation impacts and EBV-driven oncogenic pathways. These applications facilitate mechanistic research into lymphoma biology and preclinical evaluation of candidate therapeutics.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
